Insilico Medicine has secured $110 million in Series E funding to advance its AI-powered drug discovery platform, expand its biopharmaceutical research, and enhance automation through its robotic lab and AI Scientist, signaling a major leap forward in AI-driven medicine. (Source: Image by RR)

AI Meets Medicine: Insilico’s Pharma.AI Gets Massive Funding to Reshape Drug Discovery

AI-driven drug discovery company Insilico Medicine has raised $110 million in an oversubscribed Series E funding round, with participation from Value Partners Group and other new and existing investors. The company plans to use the funds to expand its drug pipeline, enhance its AI-powered Pharma.AI platform, and further develop its biopharmaceutical research and automation capabilities. Insilico’s Life Star1, a fully robotic lab, is designed to streamline research workflows alongside its AI-driven models, including Nach01, a multimodal foundation model, and Dora, a generative research assistant.

The investment, as reported in mobihealthnews.com, highlights Insilico’s position at the forefront of AI-driven drug development, with its AI scientist, Insilico, automating discovery processes to accelerate drug innovation. Value Partners Group expressed confidence in Insilico’s approach, emphasizing how AI and automation can redefine biopharmaceutical R&D and accelerate the development of life-saving therapies. The funding will also help Insilico strengthen its industry collaborations and apply its AI technology across a wider range of life sciences applications.

Earlier this year, Insilico entered a licensing agreement with Menarini Group, allowing its subsidiary, Stemline Therapeutics, to develop and commercialize an AI-discovered preclinical oncology asset. Under this deal, Insilico secured a $20 million upfront payment, with the potential for up to $550 million in milestone payments and royalties. The company has previously raised $60 million in Series D funding in 2022 and $225 million in Series C funding in 2021, underscoring its continued growth in the AI-driven drug discovery sector.

Insilico faces competition from other AI-powered biotech firms, including Manas AI, which launched earlier this year with $24.6 million in seed funding, and AION Labs, a partnership backed by AstraZeneca, Merck, Pfizer, Teva Pharmaceuticals and AWS, among others. Founded in 2021 with support from the Israeli government, AION has a portfolio of eight AI life sciences companies. As AI continues to transform drug development, Insilico remains a key player in this rapidly evolving field, leveraging its AI expertise to streamline research and bring new therapies to market faster.

read more at mobihealthnews.com